Breast Cancer Tissue: Invasive lobular carcinoma (ILC)

NCT03620643: ROS1 Targeting With Crizotinib in Advanced E-cadherin Negative, ER Positive Lobular Breast Cancer or Diffuse Gastric Cancer Study

NCT03620643
Breast Cancer Type: HR+ & HER2-negative
Hormone Mutations: ER+
Other Mutations: 
Breast Cancer Tissue: Invasive lobular carcinoma (ILC)
Recruitment Status: Recruiting
Phase 2
Drug Category: Tyrosine-Kinase Inhibitor, Endocrine (Hormone Therapy

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: 
Additional Notes: Must have diagnosis of ER+ ILC
Exclusions: Known untreated or symptomatic brain metastases requiring steroids
https://ClinicalTrials.gov/show/NCT03620643

NCT03147040: AssessinG Efficacy of Carboplatin and ATezOlizumab in Metastatic Lobular Breast Cancer

NCT03147040
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: Invasive lobular carcinoma (ILC)
Recruitment Status: Active, not recruiting
Phase 2
Drug Category: Immunotherapy, Therapeutic Antibody, Chemotherapy

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult), Senior)
Location of Metastases: 
Additional Notes: Must have diagnosis of ILC
Exclusions: Leptomeningeal disease localization
https://ClinicalTrials.gov/show/NCT03147040

Up ↑